NCT06851078View on ClinicalTrials.gov

Evaluation of Early Administration of Levetiracetam in the Prevention and Treatment Encephalopathy in Septic Shock: Randomized, Double-blind, Placebo-controlled Trial

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

March 15, 2025

Primary Completion Date

June 15, 2027

Study Completion Date

June 15, 2027

Conditions
Septic Shock
Interventions
DRUG

Levetiracetam IV

1000 mg twice a day during 7 days maximum

OTHER

Placebo control

NaCl 0.9% sodium chloride in the same route and method of administration as experimental treatment

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER